LUIS
BRIEVA RUIZ
CON
![Foto de LUIS](/img/nophoto.png)
![Foto de Universitat Autònoma de Barcelona](/img/noimage_org.png)
Universitat Autònoma de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (7)
2023
-
Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis
Brain Communications, Vol. 5, Núm. 2
2022
-
Seroprevalence of SARS‐CoV‐2 in a Cohort of Patients with Multiple Sclerosis under Disease‐Modifying Therapies
Journal of Clinical Medicine, Vol. 11, Núm. 9
2021
-
Assessing blood-based biomarkers to define a therapeutic window for natalizumab
Journal of Personalized Medicine, Vol. 11, Núm. 12
2019
-
Mitochondrial m.13513G > A Point Mutation in ND5 in a 16-Year-Old Man with Leber Hereditary Optic Neuropathy Detected by Next-Generation Sequencing
JOURNAL OF PEDIATRIC GENETICS, Vol. 8, Núm. 4, pp. 231-234
-
Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment
Mediators of Inflammation, Vol. 2019
2018
-
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients
CNS Neuroscience and Therapeutics, Vol. 24, Núm. 12, pp. 1175-1184
2011
-
Interferon beta-1b for the treatment of primary progressive multiple sclerosis: Five-year clinical trial follow-up
Archives of Neurology, Vol. 68, Núm. 11, pp. 1421-1427